A study to investigate the effect of capivasertib on the pharmacokinetics of oral dextromethorphan (CYP2D6) in healthy participants
D3615C00005
Phase 1 other active
Quick answer
A study to investigate the effect of capivasertib on the pharmacokinetics of oral dextromethorphan (CYP2D6) in healthy participants for Healthy participants is a Phase 1 program (other) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Healthy participants
- Phase
- Phase 1
- Modality
- other
- Status
- active